Search

Displaying results 6431 - 6440 of 10000 in total
  1. Drug

    Kisspeptin

    go.drugbank.com/drugs/DB19112
    Investigational

    Kisspeptin is under investigation in clinical trial NCT03315325 (Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men).

  2. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

  3. Drug

    Pirepemat

    go.drugbank.com/drugs/DB19165
    Investigational

    Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)).

  4. Drug

    Dihydromyricetin

    go.drugbank.com/drugs/DB15645
    Investigational

    Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).

  5. Drug

    Epitizide

    go.drugbank.com/drugs/DB13989
    Experimental

    Epitizide is an agent, commonly found in combination [triamterene], used to produce diuresis.

  6. Drug

    Lixudebart

    go.drugbank.com/drugs/DB19244
    Investigational

    Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]

  7. Drug

    P-nitrobiphenyl

    go.drugbank.com/drugs/DB12300
    ApprovedWithdrawn

    Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.

  8. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  9. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  10. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.